![]() |
|
|
Vol. 16, Issue 8, 3501-3510, August 2005
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(TGF
) Pathway by Interleukin-1
Is Mediated through TGF
-activated Kinase 1 Phosphorylation of SMAD3



* Developmental Genetics, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, 9751 NN Haren, The Netherlands;
Department of Hematology, University Hospital Groningen, 9713 GZ Groningen, The Netherlands
Submitted November 30, 2004;
Revised May 9, 2005;
Accepted May 17, 2005
Monitoring Editor: William Tansey
Transforming growth factor
is the prototype of a large family of secreted factors that regulate multiple biological processes. In the immune system, TGF
acts as an anti-inflammatory and immunosuppressive molecule, whereas the cytokine interleukin (IL)-1
is a crucial mediator of inflammatory responses and induces proinflammatory genes and acute phase proteins. Here, we present evidence for the existence of a direct inhibitory interaction between the IL-1
and TGF
signaling cascades that is not dependent on IL-1
induced SMAD7 expression. IL-1
and its downstream mediator TAK1 inhibit SMAD3-mediated TGF
target gene activation, whereas SMAD3 nuclear translocation and DNA binding in response to TGF
are not affected. IL-1
transiently induces association between TAK1 and the MAD homology 2 domain of SMAD3, resulting in SMAD3 phosphorylation. Furthermore, IL-1
alleviates the inhibitory effect of TGF
on in vitro hematopoietic myeloid colony formation. In conclusion, our data provide evidence for the existence of a direct inhibitory effect of the IL-1
-TAK1 pathway on SMAD3-mediated TGF
signaling, resulting in reduced TGF
target gene activation and restored proliferation of hematopoietic progenitors.
These authors contributed equally to this work.
Address correspondence to: Bart J.L. Eggen (b.j.l.eggen{at}rug.nl).
This article has been cited by other articles:
![]() |
J.-H. Zhou, Y.-G. Jiang, R.-W. Wang, S.-Z. Fan, T.-Q. Gong, Q.-Y. Tan, Z. Ma, Y.-P. Zhao, and B. Deng Prevention of stricture development after corrosive esophageal burn with a modified esophageal stent in dogs. J. Thorac. Cardiovasc. Surg., November 1, 2008; 136(5): 1336 - 1342.e7. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Lu, L. Tian, Y. Han, M. Vogelbaum, and G. R. Stark Dose-dependent cross-talk between the transforming growth factor-beta and interleukin-1 signaling pathways PNAS, March 13, 2007; 104(11): 4365 - 4370. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Behfar, C. Perez-Terzic, R. S. Faustino, D. K. Arrell, D. M. Hodgson, S. Yamada, M. Puceat, N. Niederlander, A. E Alekseev, L. V. Zingman, et al. Cardiopoietic programming of embryonic stem cells for tumor-free heart repair J. Exp. Med., February 19, 2007; 204(2): 405 - 420. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Jadrich, M. B. O'Connor, and E. Coucouvanis The TGF{beta} activated kinase TAK1 regulates vascular development in vivo. Development, April 1, 2006; 133(8): 1529 - 1541. [Abstract] [Full Text] [PDF] |
||||